Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-11-26
Design Therapeutics to Participate in Upcoming Investor ConferencesDSGN — Design Therapeutics Inc
NASDAQ · Biotechnology · Biotechnology
$12.53+37.39%Market cap692.58M
- Latest Close
- $12.53
- 30-Day Move
- +37.4%
- Market Cap
- $693M
- Shares Outstanding
- 61,670,000
- P/B Ratio
- 2.51
- ROE
- -20.6%
Analyst consensus: Buy · 12 analysts
NASDAQ:DSGNBiotechnology / BiotechnologyDelayed public snapshot
Design Therapeutics Inc
A read-only Alphactor snapshot forDesign Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$12.53
30-Day Move
+37.4%
Market Cap
$693M
Shares Outstanding
61,670,000
P/B Ratio
2.51
ROE
-20.6%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$12.53
+37.4%last 90 delayed daily bars
Market cap$693M
90D High
$13.54
90D Low
$8.23
Avg Volume
336,635
What stands out
Net margin is -3600.0%, useful for comparing DSGN against peers in Biotechnology.
DSGN is up 37.4% over the last 30 trading days shown on this page.
Latest operating income is $-18M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
58.3%
Fundamentals snapshot
Latest Close
$12.53
30-Day Move
+37.4%
Market Cap
$693M
Shares Outstanding
61,670,000
P/B Ratio
2.51
ROE
-20.6%
ROA
-19.8%
Operating Margin
-3621.7%
Net Margin
-3600.0%
Debt / Equity
0
Current Ratio
17.14
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-18M
Net Income
$-16M
Gross Margin
--
Net Margin
-360000.0%
Current Ratio
17.14
Debt / Equity
0.00
Quality snapshot
Altman Z
28.45
Safe
Piotroski
2
Weak (0-3)
Cash Conversion
0.78x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-68M | $-63M | $-52M |
| 2023-12-31 | $0 | $-78M | $-67M | $-59M |
| 2024-12-31 | $0 | $-62M | $-50M | $-43M |
| 2025-12-31 | $0 | $-79M | $-70M | $-55M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2024-05-07
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferencePublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2024-03-26
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2024-03-19
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial ResultsPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2024-03-12
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio UpdateAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 956,875 | 0.02% | 2025-12-31 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 616,831 | 0.01% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 ETF | 601,267 | 0.01% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 310,831 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 232,278 | 0.00% | 2026-01-31 |
| iShares Trust-iShares Biotechnology ETF | 234,867 | 0.00% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 Value ETF | 202,745 | 0.00% | 2026-02-28 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 156,517 | 0.00% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Vanguard Group
Filed 2026-01-29
$15M
+13.0%
BlackRock
Filed 2024-05-10
$9M
--
FMR LLC (Fidelity)
Filed 2026-02-17
$7M
+4.1%
Geode Capital Management
Filed 2026-02-09
$6M
-2.3%
Citadel Advisors
Filed 2026-02-17
$4M
--
D.E. Shaw
Filed 2026-02-17
$4M
+17.6%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.33
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
12
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.